Dragana Milojković

Imperial College Healthcare NHS Trust — United Kingdom

Medicine · Health Sciences

45h-index10.4kcitations294works6.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Chronic Myeloid Leukemia Treatments(199), Chronic Lymphocytic Leukemia Research(143), Eosinophilic Disorders and Syndromes(72), Acute Myeloid Leukemia Research(54), Myeloproliferative Neoplasms: Diagnosis and Treatment(46)

Publications293 total

Multiarm multistage randomised controlled trial of inflammatory signal inhibitors (MATIS) for patients hospitalised with COVID-19 pneumonia during the UK pandemic
BMJ Open·2026Open Access
Changes in disease responses after discontinution of tyrosine kinase inhibitors (TKI) for pregnancy in established chronic myeloid leukaemia (CML): Evidence for the basis of advice for women of child-bearing age
Blood·2025Open Access
ASC4OPT 96-week results: Asciminib once or twice daily continues to be highly efficacious and demonstrates favorable safety in patients with chronic myeloid leukemia and suboptimal response, resistance or intolerance to two or more tyrosine kinase inhibitors
Blood·2025Open Access
Changes in Common Blood Parameters After Discontinuation of Tyrosine Kinase Inhibitors for Chronic Myeloid Leukaemia
eJHaem·2025Open Access
2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia
Leukemia·2025· 43 citedOpen Access
Retrospective Study to Compare Treatment Outcomes of Asciminib Vs. Ponatinib in 99 Patients with T315I Mutated Chronic Myeloid Leukemia
Blood·2024· 2 citedOpen Access
Asciminib Shows High Efficacy and Favorable Tolerability at 80 Mg Once Daily and 40 Mg Twice Daily in Patients with Chronic Phase Chronic Myelogenous Leukemia Previously Treated with 2 or More Tyrosine Kinase Inhibitors: Primary Analysis from the ASC4OPT Study
Blood·2024· 5 citedOpen Access
RUX-AZA Response in AP/BP-MPN Is Driven By Release of the Differentiation Block in Mutant HSPCs: A Single-Cell Multi-Omic Analysis of Responders on the Phase Ib Phazar Study
Blood·2024
<i>BCR::ABL1</i> transcript Type Does Not Impact Allogeneic Stem Cell Transplant Outcome in Chronic Myeloid Leukaemia
Blood·2024
Real World Efficacy and Safety of Momelotinib for Myelofibrosis: Evaluation of a UK-Wide Study Confirms 40% Anaemia Response Rate in a Non-Clinical Trial Cohort
Blood·2024· 2 citedOpen Access
Cardiovascular events in CML patients treated with nilotinib: validation of the HFA-ICOS baseline risk score
European Heart Journal·2024
Impact of BCR::ABL1 single nucleotide variants on asciminib efficacy
Leukemia·2024· 9 citedOpen Access
Cardiovascular events in CML patients treated with Nilotinib: validation of the HFA-ICOS baseline risk score
Cardio-Oncology·2024· 13 citedOpen Access
Expectations and outcomes of varying treatment strategies for <scp>CML</scp> presenting during pregnancy
British Journal of Haematology·2024· 9 citedOpen Access
Effect of tyrosine kinase inhibitors on male fertility in patients with chronic phase chronic myeloid leukemia
Leukemia & lymphoma/Leukemia and lymphoma·2024· 9 citedOpen Access
Treatment‐free remission in <scp>CML</scp> patients with additional chromosome abnormalities in the Philadelphia‐positive clone or variant Philadelphia translocations
American Journal of Hematology·2024· 4 citedOpen Access
Long-term outcomes after upfront second-generation tyrosine kinase inhibitors for chronic myeloid leukemia: managing intolerance and resistance
Leukemia·2024· 20 citedOpen Access
Treatment for First Cytomegalovirus Infection Post–Hematopoietic Cell Transplant in the AURORA Trial: A Multicenter, Double-Blind, Randomized, Phase 3 Trial Comparing Maribavir With Valganciclovir
Clinical Infectious Diseases·2023· 44 citedOpen Access
Tamoxifen for the treatment of myeloproliferative neoplasms: A Phase II clinical trial and exploratory analysis
Nature Communications·2023· 8 citedOpen Access
Incidence, Interpretation and Management of Liver Function Abnormalities in Patients with Chronic Myeloid Leukemia (CML) Treated with Tyrosine Kinase Inhibitors (TKI)
Blood·2023Open Access
page 1 of 15Next →

Frequent Co-authors

Jane F. Apperley(36), John M. Goldman(21), Letizia Foroni(19), David Marín(18), Alistair Reid(17), Hugues de Lavallade(17), Richard Szydlo(16), Jamshid S. Khorashad(15), Richard E. Clark(13), Marco Bua(12), Katayoun Rezvani(11), Eduardo Olavarría(7), Gareth Gerrard(7), Jiří Pavlů(7), Christos Paliompeis(6), Katy Rezvani(6), Amr R. Ibrahim(5), Jenny Byrne(5), Mhairi Copland(5), Aristeidis Chaidos(5)